Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

@article{Weisberg2007SecondGI,
  title={Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia},
  author={Ellen L. Weisberg and Paul W. Manley and Sandra W. Cowan-Jacob and Andreas Hochhaus and James D. Griffin},
  journal={Nature Reviews Cancer},
  year={2007},
  volume={7},
  pages={345-356}
}
Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein. However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance. Several second-generation ABL kinase inhibitors have been or are being developed for… 
Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?
TLDR
Progress made in the treatment of CML in the past year is highlighted, including dose optimization of imatinib, combination therapy, upfront use of second-generation TKIs, and use of maintenance therapy with interferon-α and vaccines.
Strategies for overcoming imatinib resistance in chronic myeloid leukemia
TLDR
The availability of dasatinib and development of other tyrosine kinase inhibitors provide positive prospects for patients with imatinib-resistant or -intolerant CML, and several new strategies for treating patients afterImatinib failure are discussed.
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice
TLDR
Mechanisms of imatinib resistance and preclinical and clinical data with dasatinib and nilotinib which may have potential use for guiding second-line treatment decisions are discussed.
New insights into small‐molecule inhibitors of Bcr‐Abl
TLDR
This review will report the most interesting second‐generation Abl and dual Src/Abl inhibitors recently entered in clinical trial, but also the new ATP‐competitive and uncompetitive inhibitors published in the last few years, focusing on their chemical structure, mechanism of action, and structure–activity relationship.
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
TLDR
Testing for mutations in BCR-ABL1 may predict lack of response to imatinib or may inform the choice of alternative TKIs, as well as inspire the development of new drugs that target additional disease mechanisms.
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
TLDR
Although not all resistance mechanisms have been identified and understood, several agents based on the known mechanisms have already been designed and developed and are beginning clinical trials.
Imatinib resistance in CML.
TLDR
The molecular basis of imatinib resistance, the significance of molecular monitoring and the current efforts to overcome imatin ib resistance are described, ranging from the development of new drugs to the stimulation of an immune response against the disease.
Therapy options in imatinib failures.
TLDR
New treatment approaches are required for patients resistant to or intolerant of imatinib, which can be dose escalated in patients who demonstrate resistance, and less clinically advanced strategies are discussed in this review.
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
  • Ke Yang, L. Fu
  • Medicine
    Critical reviews in oncology/hematology
  • 2015
TLDR
This review summarized BCR-ABL inhibitors approved by Food and Drug Administration (FAD), with the same concerns focus on the resistant mechanisms of B CR-ABl inhibitors and therapeutic resistant strategies.
Roots of imatinib resistance: a question of self-renewal?
  • A. Burchert
  • Biology, Medicine
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2007
TLDR
It is proposed here that alternative genetic aberrations, which synergize with BCR-ABL to enable leukemic self-renewal are of causal importance for the evolution of clinical kinase inhibitor resistance.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
TLDR
The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein is responsible for the transformation of haematopoietic stem cells and the symptoms of chronic myeloid leukaemia, andconsiderable progress has recently been made in understanding the structural biology of Abl and the molecular basis for resistance.
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
TLDR
In this review, the early characterisation and development of AMn107 is discussed, as is the current status of AMN107 in clinical trials for imatinib-resistant CML and Ph+ ALL.
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
TLDR
BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinIB-resistant BCR-ABL mutants and illustrates how molecular insight into kinase inhibitors resistance can guide the design of second-generation targeted therapies.
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
TLDR
It is reported that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for allImatinib-resistant mutants tested, with the exception of T315I.
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
  • K. Gumireddy, S. Baker, +5 authors E. Reddy
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
Kinetic studies demonstrate that this compound is not ATP-competitive but is substrate-competitive and works synergistically with imatinib in wild-type BCR-ABL inhibition, and ON012380 was found to induce apoptosis of all of the known imatin ib-resistant mutants at concentrations of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection.
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
TLDR
The reasons for relapse are reviewed, resistance resulting from Bcr-Abl tyrosine kinase domain mutations at the molecular level is analyzed, and strategies to potentially circumvent or overcome resistance are discussed.
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
TLDR
Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
TLDR
The discovery of a new class of Bcr-abl inhibitors is reported using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library and it is proposed that this newclass of compounds inhibits BCr-abl kinase activity through an allosteric non-ATP competitive mechanism.
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
TLDR
Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of d asatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.
Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib
TLDR
The results indicate that Src/Abl inhibitors are compatible with imatinib and suggest that combined Abl inhibitor therapy is a feasible treatment strategy for patients with CML.
...
1
2
3
4
5
...